Generate Biomedicines, Inc. (GENB) vs Xeris Biopharma Holdings, Inc. (XERS)
A side-by-side comparison of Generate Biomedicines, Inc. and Xeris Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GENB
Generate Biomedicines, Inc.
$13.86HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
XERS
Xeris Biopharma Holdings, Inc.
$10.03HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Total return — GENB vs XERS
growth of $100 · dividends reinvested · last 1yGENB +10.0% (+10.0%/yr)XERS +52.1% (+52.1%/yr)XERS compounded faster over this window
GENB XERS
GENB vs XERS: by the numbers
- •GENB is the larger company ($1.78B vs $1.73B market cap).
- •Both run net losses; XERS's is the smaller (-5.12% vs -636.99% net margin).
Metrics side by side
Valuation
| Metric | GENB | XERS |
|---|---|---|
| P/S ratio | N/A | 5.16 |
| P/B ratio | 3.89 | N/A |
| EV / EBITDA | N/A | 38.69 |
| FCF yield | N/A | 3.20% |
Profitability
| Metric | GENB | XERS |
|---|---|---|
| Gross margin | 100.00% | 83.34% |
| Operating margin | -737.04% | 10.91% |
| Net margin | -636.99% | -5.12% |
| ROIC | -94.79% | 12.79% |
Growth (annualized)
| Metric | GENB | XERS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 58.33% |
| Total return CAGR (5Y) | N/A | 33.72% |
Go deeper
Dig into the metrics
Generate Biomedicines ROEXeris Biopharma ROEGenerate Biomedicines operating marginXeris Biopharma operating marginGenerate Biomedicines revenue growthXeris Biopharma revenue growthGenerate Biomedicines free cash flowXeris Biopharma free cash flow
Generate Biomedicines & Xeris Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.